Through its polymer-based drug delivery, Eluvia transfers the majority of the drug to the tissue and minimizes downstream particulates.
New Eluvia 2-year TLR data shows very low revascularization rates with polymer-based delivery, even in high-risk patients.
“The safety profile of our Eluvia stent correlates with safety data from patients treated with Boston Scientific TAXUS paclitaxel-eluting stents”
Ian T. Meredith, MBBS, PhD, AM
As a polymer-based drug eluting stent, Eluvia is more like coronary stents, such as Boston Scientific's TAXUS, versus peripheral paclitaxel-coated products. Both Eluvia and TAXUS deliver the same drug and are similar in design intent and mechanism of action; both yielding sustained, targeted paclitaxel delivery.
- In the MAJESTIC Clinical Trial, Eluvia demonstrated a 3.6% all-cause mortality rate at 3 years, which is in line or lower than with non-coated devices*
- As published in JACC:CI, TAXUS demonstrated a 9.8% all-cause mortality rate at 5 years, compared to 9.1% in the BMS arm (p-value = 0.53)
* Innova Bare Metal Stent (SuperNOVA Trial) 3-year All-Cause Mortality: 7.9%
A 5-year patient-level pooled meta analysis
from randomized, controlled trials, published in JACC:CI, from 2,797 patients (TAXUS DES vs. BMS) showed no difference in mortality
5 year data in PAD patients
(TAXUS DES vs PTA + BMS) showed no difference in mortality in CLI
Stay Up to Date
Receive emails about the latest drug-eluting technology news, innovations and events in your area.
Explore DE Resources
Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.